Skip to main content
TipRanks
Go Ultimate75% OFF

OncoZenge AB (8LY) Stock Price & Analysis

0 Followers

8LY Stock Chart & Stats

€0.28-€0.00(-0.36%)
At close: 5:30 PM GMT+1
€0.2€0.4€0.6Nov 16Jun 16Jan 15Aug 26Jan 20
Day’s Range
EUR 0.28 - EUR 0.28
52-Week Range
EUR 0.23 - EUR 0.63
Previous Close
EUR 0.28
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 8.07M
Enterprise Value
EUR 108.32M
Total Cash (Recent Filing)
EUR 24.30M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
0.71
Next Earnings
Feb 18, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance Sheet

The current debt-free position and positive equity provide financial flexibility while the company develops its oncology products. Low leverage reduces interest burden and refinancing pressure, giving management more room to allocate capital toward commercialization and operational needs.

Solid Gross Margin

A gross margin near 68% indicates that the product economics can retain a meaningful portion of revenue after direct costs. If revenue recovers and operating spending becomes more disciplined, this underlying margin profile could support improved contribution toward fixed costs and eventual profitability.

Focused Oncology Supportive Care

The focused product strategy targets a specific unmet supportive-care need in oncology rather than pursuing a broad pharmaceutical portfolio. Concentration on severe cancer pain and treatment-related oral mucositis can help align development and commercialization resources around a defined clinical application.

Bears Say

Persistent Cash Burn

Materially negative operating and free cash flow show that the business is not yet funding itself from operations. Continued cash burn can require additional financing or a rapid improvement in revenue and costs, potentially limiting strategic flexibility over the coming quarters.

Revenue Volatility

The sharp decline in revenue highlights limited consistency in the current commercial base. Unstable sales make it harder to forecast cash generation, plan investment, or spread operating costs efficiently, leaving the company more exposed until demand and commercialization become more dependable.

Deep Operating Losses

The scale of operating and net losses shows that current revenue is far below the level needed to cover the cost base. Even with a solid gross margin, sustained losses can consume equity and require significant improvement in sales productivity or expense discipline to reach breakeven.

8LY FAQ

What was OncoZenge AB’s price range in the past 12 months?
OncoZenge AB lowest stock price was €0.23 and its highest was €0.63 in the past 12 months.
What is OncoZenge AB’s market cap?
OncoZenge AB’s market cap is €8.07M.
When is OncoZenge AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were OncoZenge AB’s earnings last quarter?
OncoZenge AB released its earnings results on Aug 27, 2026. The company reported -€0.03 earnings per share for the quarter.
Is OncoZenge AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does OncoZenge AB pay dividends?
OncoZenge AB does not currently pay dividends.
What is OncoZenge AB’s EPS estimate?
OncoZenge AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoZenge AB have?
OncoZenge AB has 27,601,244 shares outstanding.
What happened to OncoZenge AB’s price movement after its last earnings report?
OncoZenge AB reported an EPS of -€0.03 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of OncoZenge AB?
Currently, no hedge funds are holding shares in DE:8LY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology